Study Data (84,990 patients): Patients on GLP-1 agonists had lower rates of: - Acute myocardial infarction - Atrial fibrillation - Stroke - Kidney failure Benefits were confirmed even in patients already taking SGLT2 inhibitors
Even pharmaceutical companies without GLP-1 medications on the market lobbied on weight loss drug pricing, including Boehringer Ingelheim, which has several weight loss drugs in clinical trials
doi: 10.3389/fphar.2025.1562896 Received 23 January 2025 Accepted 05 May 2025 Published 02 June 2025 Corrected 09 June 2025 Volume 16 - 2025 Edited by Ahmed Ghallab, Leibniz Research Centre for Working Environment and Human Factors (IfADo), Germany Reviewed by Madlen Matz-Soja, Leipzig University, Germany Mohamed Albadry, University Hospital Jena, Germany Updates Copyright 2025 Sun, Shang, Lv, Liu, Wu and Geng
Metformin was dosed twice daily (one tablet of Glucophage 500 mg) in two periods of 3.5 days before and with semaglutide, to obtain steady-state conditions and minimise the potential of within-subject variation in metformin bioavailability [20]